ClinicalTrials.gg
Status unknownNCT04807699RecoversusUpdated Mar 19, 2021

Collaborative Network for Generating Scientific Evidence in COVID-19 For the Unified Health System in Brazil - RECOVER SUS-BRASIL

An observational study in Covid19 and Hospitalization, sponsored by Evandro Chagas National Institute of Infectious Disease. Status unknown at 13 sites in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-03-19.

Sponsored by Evandro Chagas National Institute of Infectious Disease · Observational

How we know

The sponsor has not verified this record recently (last verified Mar 2021), so the status shown — last known as Enrolling by invitation — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
3,500
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 317 studies in COVID-19 with a site in Brazil — 20 open to participants now, 28 under way, 9 of them phase 3. COVID-19 · Brazil.

Planned enrollment
8th of 54
3,500 · median 598
Started
2020
with 152 others
Observational
54 of 317
3 open now
Registered
194th of 317
by date

Among the 317 studies in COVID-19 with a site in Brazil, this one is the 8th largest by planned enrollment of the 54 observational ones that give a count, is one of 153 that started in 2020, is one of 54 observational ones, and was the 194th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

20 of the 317 studies in COVID-19 with a site in Brazil are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 317 studies in COVID-19 with a site in Brazil, or all of them as a file.
02

Study summary

The RECOVER SUS-BRASIL network, made up of excellent academic and research institutions, was formed in response to the emergence of unprecedented public health related to SARS-CoV-2. The Network's objectives are the production of scientific knowledge, the technical and scientific strengthening of participating centers, the sharing of information and experiences with other assistance services and the generation of evidence for public health policies in Brazil. The present proposal aims to increase the magnitude of the Network, proposing two studies to assess the epidemic of COVID-19 in Brazil. The first study deals with the establishment of a prospective cohort of patients hospitalized for COVID-19. Through using standardized data collection procedures, biological samples and biomarkers, this study will be able to describe clinical presentation, severity, risk factors for worsening of the disease. Multiple clinical outcomes of severity of disease, organ dysfunction, hospital mortality, length of hospital stay, hospital readmission and early post-discharge death. Will be biomarkers of inflammation, cellular and humoral immunity were also evaluated to study their association with clinical outcomes, variability of SARS-CoV-2 and the development of immunity in infected individuals through the detection and titration of neutralizing antibodies anti-SARS-CoV-2. The second study 2 will evaluate the COVID-19 epidemic in people living with HIV / AIDS, using SUS databases, such as SIM, SICLOM and SISCEL. This study is particularly relevant since on the one hand it includes a population potentially at greater risk of developing severe forms of the disease, given their underlying condition, as, on the other hand, they are exposed chronically to drugs that could potentially have an effect on SARS-CoV-2. Finally, a major objective of RECOVER SUS-BRASIL is integrate technical and scientific capacities generating scientific production of high relevance and impact and strengthening health and science throughout the country.

Read the detailed description

Study 1 procedures are clinical and sociodemographic data collected through interview at admission and results of complementary exams performed during hospitalization. Data will be collected during the participant's inclusion visit (Day 0,equivalent to the date of hospital admission) and subsequently according to in-hospital visits untill discharge moment.

The team of researchers will have access to the electronic medical record or, as the case, to the paper medical record for the collection of data and variables of the study interest, and questionnaires with specific questions from participants or family members.

A visit in 31-60 days will be made, by telephone contact, for the application by a health professional of a questionnaire on mental health and verification of the occurrence of death or hospital readmission. The mental health questionnaire includes tracking disorders, such as: depression, anxiety, post-traumatic stress disorder, suicidal ideation and insomnia [questionnaires PHQ-9, GAD-7, Abbreviated PCL-C and Index Severity of Insomnia], in addition to a questionnaire on social support [MSPSS]. Patients identified with health disorders over the telephone will be referred to specialized care by a psychiatrist. Study 2 - Data from information systems drug dispensation (SICLOM - http://www.aids.gov.br/pt-br/gestores/sistemas-de-informacao/sistema-de-controle-logistico-demedicamentos-siclom), laboratory tests (SISCEL - http : //www.aids.gov.br/pt-br/sistema-de-informacao/sistema-de-controle-de-exameslaboratoriais-da-rede-nacional-de-contagem-de), information on mortality (SIM - http://sim.saude.gov.br/) and COVID-19 case notification database will be released to the Ministry of Health, with data identified with patient name, mother's name and date of birth to enable the linkage process. This sensitive data is obtained through specific forms, which include confidentiality clauses of the data. All transport and storage of this data, whether by digital physical means (for example, CD) or via the web, will be done in encrypted form with a strong algorithm. The final database will be de-identified to guarantee the confidentiality of the participants.

03

Conditions studied

  • Covid19
  • Hospitalization

Browse trials for

Keywords

  • Covid-19
  • hospitalization
  • biomarkers
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Adults aged 18 years. Hospitalized for suspicious signs and symptoms of COVID-19 infection by the medical care team or confirmed by laboratory tests such as RT-PCR or rapid tests.

Eligibility criteria

Inclusion Criteria:Adults aged 18 years. Hospitalized for suspicious signs and symptoms of COVID-19 infection by the medical care team or confirmed by laboratory tests such as RT-PCR or rapid tests.

Exclusion Criteria:Patient or family member refusal

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
3,500 participants (estimated)
Target follow-up
2 Months
Patient registry
Yes

Groups and cohorts

  • Total participants

    3500 participants that will have their medical forms checked

    Other: Data collection

Interventions

  • OtherData collection

    Clinical and sociodemographic data collected through interview at admission and results of complementary tests performed during hospitalization.

06

What researchers measure

Primary outcomes

  1. The main outcome of the study is hospital mortality

    Time frame: 25/05/2021

Secondary outcomes

  1. Length of hospital stay

    Time frame: 25/05/2021

07

Study locations

13 sites
  • Hospital Couto Maia/SES/BA
    Salvador, Bahia 41332-150, Brazil
  • Hospital São José de Doenças Infecciosas - HSJ / Secretaria de Saúde Fortaleza
    Fortaleza, Ceará 60455-610, Brazil
  • Universidade Federal de Minas Gerais
    Belo Horizonte, Minas Gerais 31270-901, Brazil
  • Hospital Nossa Senhora da Conceição
    Porto Alegre, Rio Grande Do Sul, Brazil
  • Universidade Federal de Santa Maria/ Pró-Reitoria de PósGraduação e Pesquisa
    Santa Maria, Rio Grande Do Sul 97105-900, Brazil
  • Hospital dos Servidores do Estado/RJ
    Rio de Janeiro, RJ 20221-161, Brazil
  • Hospital Universitário Gaffree e Guinle/HUGG/UNIRIO
    Rio de Janeiro, RJ 20270-004, Brazil
  • Hospital Universitário Pedro Ernesto/UERJ
    Rio de Janeiro, RJ 20551-030, Brazil
  • Instituto Nacional de Infectologia Evandro Chagas (Fiocruz)
    Rio de Janeiro, RJ 21040-360, Brazil
  • Universidade Federal do Rio de Janeiro
    Rio de Janeiro, RJ 21941-617, Brazil
  • Hospital Regional de São José
    São José, Santa Catarina 88103-310, Brazil
  • Hospital Estadual Sumaré Dr. Leandro Francheschini
    Sumaré, São Paulo 13174-530, Brazil
  • Instituto de Infectologia Emílio Ribas
    São Paulo, 01246-900, Brazil
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2020 (actual). Primary completion is estimated for Oct 2021, 15 months after the start.

Of 1,640 non-industry observational studies under COVID-19, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 30. This study's planned 15 months is close to that.

Counting every sponsor, half of 1,774 studies reached it within 13 months; a quarter within 5 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2021
First posted
Mar 19, 2021
StartActual
Jul 25, 2020
Primary completionEst.
Oct 25, 2021
CompletionEst.
Mar 25, 2022
Last update
Mar 19, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04807699
Lead sponsor
Evandro Chagas National Institute of Infectious Disease
Collaborators
Hospital Universitario Pedro Ernesto, Universidade Federal do Rio de Janeiro, Hospital Couto Maia/SES/BA, Hospital São José de Doenças Infecciosas - HSJ / Secretaria de Saúde Fortaleza, Hospital Estadual Sumaré Dr. Leandro Francheschini, Universidade Federal de Santa Maria, Hospital Regional de São José - Dr. Homero de Miranda Gomes, Hospital dos Servidores do Estado do Rio de Janeiro, Federal University of Minas Gerais, Gaffree & Guinle Universitary Hospital, Hospital Nossa Senhora da Conceicao, Instituto de Infectologia Emílio Ribas
Responsible party
Raquel Malaguthi de Souza (Beatriz Grinsztejn, MD, PhD, Evandro Chagas National Institute of Infectious Disease) — Principal investigator
First posted
Mar 19, 2021
Start date
Jul 25, 2020
Primary completion
Oct 25, 2021 (estimated)
Completion
Mar 25, 2022 (estimated)
Last update
Mar 19, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion